Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) announced that senior Canadian government and diplomatic officials visited its Self-Driving Lab installation at the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) in Seoul on October 28, 2026. The visit occurred during BIOPLUS-INTERPHEX Korea 2026, where Canada holds Country of Honour status and Telescope is part of the official Canadian business delegation. The milestone underscores the company's growing international profile as KPBMA simultaneously launched a multi-week training programme for Korean biopharma researchers using the platform.

Key Points

  • Telescope Innovations Corp. (CSE: TELI) is a developer of Physical AI systems and Self-Driving Laboratories for the pharmaceutical and chemical industries.
  • Senior Canadian officials, including Deputy Minister of Innovation, Science and Economic Development Canada Philip Jennings, toured the KPBMA Self-Driving Lab in Seoul.
  • The KPBMA installation, completed in December 2025, is South Korea's first pharmaceutical Self-Driving Lab; KPBMA represents approximately 300 member companies.
  • Investors may be watching whether the high-profile government visit and active researcher training programme accelerate further commercial adoption in the Korean market.

Canadian Government Delegation Visits KPBMA's Seoul Self-Driving Lab

The delegation that toured the KPBMA facility included Philip Jennings, Deputy Minister of Innovation, Science and Economic Development Canada, accompanied by senior representatives from ISED and the Embassy of Canada to the Republic of Korea. Discussions focused on emerging innovation ecosystems in AI and automation for biopharma, as well as opportunities to strengthen collaboration between Canadian and Korean innovators. The release states the visit is a meaningful step toward deepening the Canada-Korea partnership in AI-driven drug discovery and laboratory automation, according to Junhee Pyo, Director of the AI Discovery Institute at KPBMA.

South Korea's First Pharmaceutical SDL Now Training Biopharma Researchers

Installed by Telescope in December 2025, the KPBMA system is described in the announcement as South Korea's first Self-Driving Lab dedicated to pharmaceutical research, development, and education. KPBMA is Korea's largest pharmaceutical and biotech industry association, representing approximately 300 domestic and multinational member companies. Coinciding with the delegation visit, KPBMA launched a multi-week SDL training programme this week, giving researchers from Korean biopharmaceutical organisations hands-on experience with Telescope's platform, which automates chemistry experiments to increase speed, reliability, throughput, and scientific insight.

KPBMA Deployment Among Three SDL Installations Completed in Fiscal Year 2026

Professor Jason Hein, Founder and CTO of Telescope, is quoted in the release stating that the KPBMA lab was the first of three SDL deployments the company completed in fiscal year 2026, followed by Pfizer in the United States and a major global pharmaceutical company in Europe. Telescope also develops and sells enabling technologies, including the DirectInject-LC™ reaction sampling system, and provides contract process development services. The immediate share price impact was not clear from available public information.